As of October 22, 2026, Summit Therapeutics PLC (SMMT) trades at $15.62. No model fair value is published for SMMT. SMMT reports its financial statements in GBP. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar.
Source: Equity Rank — SMMT valuation (data as of 2026-10-22). The full page shows the company’s fundamental profile and earnings data.
Reported EPS came in above the analyst estimate in 1 of the last 8 reports. The median share-price change across a report, in either direction, was 3.8%.
| Report | EPS estimate | EPS actual | vs estimate | Price change |
|---|---|---|---|---|
| Jul 23, 2026 | $-0.26 | $-0.28 | -7.7% | -8.8% |
| Apr 30, 2026 | $-0.12 | $-0.18 | -45.2% | +3.0% |
| Feb 23, 2026 | $-0.01 | $-0.21 | -2000.0% | +0.2% |
| Oct 20, 2025 | $-0.04 | $-0.23 | -475.0% | -4.5% |
| Aug 11, 2025 | $-0.09 | $-0.12 | -33.3% | -1.4% |
| May 1, 2025 | $-0.07 | $-0.07 | +0.7% | +2.3% |
| Feb 24, 2025 | $-0.06 | $-0.06 | 0.0% | -14.8% |
| Oct 30, 2024 | $-0.05 | $-0.06 | -20.0% | -14.6% |
Equity Rank's fundamental strength composite scores SMMT at 38.6/100 (D+, Mixed), blending profitability, balance-sheet, and cash-flow quality. Its SAVE composite score has moved -0.8 over the past 30 days.
SMMT reports its financial statements in GBP. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar. Informational only — not investment advice.
Summit Therapeutics PLC (SMMT) is analyzed on Equity Rank with multiple valuation methods (DCF, Graham Number, multiples) and a Fundamentals Score built from value, growth, quality and financial stability. Where the data supports one, Equity Rank publishes a multi-method consensus fair value; none is published for this company at present.
Summit Therapeutics PLC (SMMT) is classified in the Biotechnology sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
All Biotechnology stocks with model fair values
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks
Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/SMMT. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Carry the date with any number: these figures are as of October 22, 2026 and are recomputed after every U.S. market close.